Phase 1/2 Trial of 4D-710, Aerosol Gene Therapy for CF, May Soon Start

Phase 1/2 Trial of 4D-710, Aerosol Gene Therapy for CF, May Soon Start

308541

Phase 1/2 Trial of 4D-710, Aerosol Gene Therapy for CF, May Soon Start

A Phase 1/2 clinical trial of an aerosol gene therapy candidate, 4D-710, in people with cystic fibrosis (CF) has been cleared by U.S. Food and Drug Administration (FDA) and is expected to start this year, its developer, 4D Molecular Therapeutics, announced. The trial is designed as an open-label, dose-escalation and dose-expansion study, which means that all enrolled will be treated (no placebo group), and the amount of 4D-710 given will increase in each new group of…

You must be logged in to read/download the full post.